Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$68.55 USD

68.55
1,391,330

+1.18 (1.75%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $68.55 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bruker (BRKR) Q4 Earnings Meet Estimates, Revenues Surpass

by Zacks Equity Research

Robust performance by the BSI and BEST segments drove Bruker's (BRKR) fourth-quarter top line.

Zacks Equity Research

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.

Zacks Equity Research

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Zacks Equity Research

DaVita's (DVA) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) strength in dialysis patient service revenues drives its Q4 top line.

Zacks Equity Research

Phibro (PAHC) Q2 Earnings Surpass Estimates, 2022 View Up

by Zacks Equity Research

Phibro (PAHC) reports better-than-expected earnings for the fiscal second quarter. Robust performances by the Animal Health and Mineral Health segments drove the top line.

Zacks Equity Research

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.

Zacks Equity Research

Illumina (ILMN) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Record shipments for both clinical and research with strength in oncology testing, genetic disease testing, and population genomics drove Illumina (ILMN) Q4 revenues.

Zacks Equity Research

Should You Buy Henry Schein (HSIC) Ahead of Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Zacks Equity Research

Here's Why You Should Retain Abbott (ABT) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.

Zacks Equity Research

STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.

Zacks Equity Research

Baxter (BAX) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Baxter's (BAX) strong product portfolio.

Zacks Equity Research

What's in the Cards for Henry Schein (HSIC) in Q4 Earnings?

by Zacks Equity Research

Solid demand in the global dental market along with an increase in COVID-19 test demand are likely to have contributed to Henry Schein's (HSIC) Q4 performance.

Zacks Equity Research

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.

Zacks Equity Research

HSIC or CNMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HSIC vs. CNMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength across its business segments.

Zacks Equity Research

CVS Health (CVS) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Strength in all three operating segments drove CVS Health's (CVS) revenues in the fourth quarter of 2021.

Zacks Equity Research

QIAGEN (QGEN) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.

Zacks Equity Research

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Increase in number of orders for Cologuard and new study findings supporting the Oncotype DX are likely to have contributed to Exact Sciences' (EXAS) Q4 performance.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.

Zacks Equity Research

Is Exscientia PLC Sponsored ADR (EXAI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Exscientia PLC Sponsored ADR (EXAI) and Henry Schein (HSIC) have performed compared to their sector so far this year.

Zacks Equity Research

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Henry Schein (HSIC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays

by Zacks Equity Research

IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.